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Percutaneous Leaflet Repair and
Annuloplasty for Mitral Regurgitation
Ted Feldman, MD, Mehmet Cilingiroglu, MD
Evanston, Illinois
Percutaneous therapy for the treatment of mitral regurgitation has emerged rapidly over the past few years.
Most of the percutaneous approaches are modifications of existing surgical approaches to mitral annuloplasty or
leaflet repair. Catheter-based devices mimic these surgical approaches with less procedural morbidity and mor-
tality as a consequence of their less invasive nature. Percutaneous annuloplasty can be achieved indirectly via
the coronary sinus or directly from retrograde left ventricular access. Catheter-based leaflet repair is accom-
plished using an implantable clip to mimic the surgical edge-to-edge technique. Several of these percutaneous
approaches have been successfully used in patients to demonstrate proof of concept, while others have already
stopped further development. There is increasing experience in both trials and practice to begin to define the
clinical utility of percutanenous leaflet repair, and annuloplasty approaches are undergoing significant
development. (J Am Coll Cardiol 2011;57:529–37) © 2011 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2010.10.012a
s
p
u
i
r
p
o
l
o
A
A
f
v
t
a
t
c
p
v
m
t
e
i
l
f
t
dinimally invasive approaches have been developed in
lmost every field in surgery. Beating-heart surgery and port
urgery are 2 approaches that have been used for many years
or valvular heart disease, including the development of
obotic operations to minimize invasiveness and diminish
he recovery time and morbidity of traditional surgery. Over
he last several years, the potential to treat patients with
alvular disease using entirely catheter-based, percutaneous
ethods has undergone rapid development. The new con-
epts and improvements in technology responsible for this
evelopment are remarkable, and illustrate a substantial
ffort by cardiovascular surgeons working in concert with
ardiologists, engineers, and clinicians (1,2).
Percutaneous therapies for mitral regurgitation (MR)
arallel surgical approaches that have been in use for many
ears, and have been largely evolved from concepts devel-
ped by surgeons. The predominant form of surgical mitral
epair is annuloplasty. The placement of a ring around the
itral annulus, fixed by sutures to diminish the mitral
rifice, is the most frequently used surgical therapy. Annu-
oplasty brings the leaflet edges closer together by dimin-
shing the circumference of the mitral orifice, and also
ecreases the distance between the septal and lateral dimen-
ions of the mitral orifice. The unique geometry of the
itral valve (MV) and apparatus creates some challenges for
nnuloplasty, and has led to the development of a variety of
rom the NorthShore University HealthSystem, Evanston, Illinois. Dr. Feldman
eceives research grants and is a consultant to Abbott and Edwards. Dr. Cilingiroglu
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010, accepted October 28, 2010.symmetric annuloplasty ring shapes to accommodate the
addle shape of the MV, and the displacement of the
osterior leaflet in cases of ischemic MR. Annuloplasty is
sed as an adjunctive therapy in all forms of MR repair,
ncluding functional ischemic and functional heart failure-
elated MR, and in conjunction with leaflet resection for
atients with degenerative MR from MV prolapse. The
ther form of repair that is commonly used in surgery is
eaflet repair. This is applied to patients with mitral prolapse
r fibroelastic deficiency.
nnuloplasty Approaches
nnuloplasty is the mainstay of surgery in patients with
unctional MR. Annular dilation due to dilation of the left
entricle and geometric distortion of the mitral apparatus is
he mechanism of MR in this group of patients. Surgical
nnuloplasty has been the predominant approach for func-
ional MR. Importantly, it has been difficult to demonstrate
linical benefit from surgical mitral repair in the heart failure
opulation. Pivotal trials of percutaneous annuloplasty de-
ices may thus make comparisons of device therapy with
edical therapy for heart failure rather than being compared
o surgical annuloplasty. The degree of efficacy necessary to
ffect clinical improvements from any form of annuloplasty
n the heart failure population has not been clearly estab-
ished from prior surgical experience, and the trial pathway
or developing these devices will necessarily answer many of
hese long-standing questions (3,4).
Percutaneous annuloplasty approaches have been both
irect and indirect. Indirect approaches use the coronary
inus as a route to deliver a device that partially encircles the
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Percutaneous Mitral Valve Therapy February 1, 2011:529–37mitral annulus. The coronary si-
nus parallels the posterior mitral
leaflet, and since there is a long
history of implantation of devices
in the coronary sinus, this ap-
peared to be an attractive route.
Access to the coronary sinus
hrough jugular puncture is well developed and simple. The
oronary sinus encircles about two-thirds of the mitral
nnulus, so a device can capture most of the annular
ircumference. Early animal work demonstrated that coro-
ary sinus devices could reduce the annular circumference
ignificantly both in the normal MV and in models of MR
reated using pacing-induced heart failure (5).
ndirect annuloplasty approaches. Several approaches to
he coronary sinus annuloplasty have been developed (Fig. 1).
undamentally, all of them place a device that creates tension
r a constricting force transmitted to the MV and the mitral
nnulus. The obvious appeal of the coronary sinus approach is
implicity and ease of use. The Cardiac Dimensions Carillon
ystem (Cardiac Dimensions, Kirkland, Washington), the
dwards Monarc system (Edwards Lifesciences, Irvine, Cali-
ornia), and the Viacor PTMA system (Viacor, Wilmington,
assachusetts) represent the coronary sinus devices that have
ome human implant experience.
Abbreviations
and Acronyms
LV  left ventricular
MR  mitral regurgitation
MV  mitral valve
Figure 1 Coronary Sinus Annuloplasty: The Cardiac Dimensions
The guide catheter is introduced through jugular venous access. The device is deli
pulled back to release the device in the coronary sinus ostium. The insets show thThe Cardiac Dimensions Carillon device (Fig. 1) is a
imple nitinol wire that has been engineered into a form
hat includes distal and proximal anchors and a bridge
lement (6). After jugular puncture, a 9-F guide catheter is
elivered into the distal coronary sinus. The distal anchor of
he device is released, and using the guide catheter to pull
rom above and place tension on the coronary sinus, the
itral circumference is shortened; then, the proximal an-
hor is released. The first generation of the device was
hallenged by difficulty in anchoring. This problem was
apidly corrected with improvements in engineering, and
ome first-in-human experience has been successfully
chieved. The major findings with this device include the
bility to reduce MR by at least 1 grade in the majority of
atients, with improvements in left ventricular (LV) vol-
mes and dimensions. As a clinical measure, 6-min walk
est results have been improved in this group as well, up to
months after treatment (7). Defining clinical success has
een a challenge in the field of MR therapy. The subjectivity
f New York Heart Association functional class is well
ppreciated. There has been no real study of the correlation
etween MR grade reduction and measures of functional
mprovement. While 6-min walk tests also have important
imitations, this measure is at least quantitative, and is being
llon Device
in the distal coronary sinus, and then the guide catheter is
form, made of nitinol wire. Figure illustration by Craig Skaggs.Cari
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February 1, 2011:529–37 Percutaneous Mitral Valve Therapydopted with increasing frequency in trials evaluating per-
utaneous valve therapies.
The Edwards Monarc device is similarly implanted in the
oronary sinus after cannulation with a guide catheter (8,9).
he device is composed of proximal and distal self-
xpanding conventional nitinol stents connected by a bridge
lement. The distal anchor is delivered into the anterior
nterventricular vein, and the proximal anchor is placed near
he coronary sinus ostium. Thus, this device captures a
reater part of the circumference of the mitral annulus than
oes the Cardiac Dimensions device. The bridge is a spring
hat is held in its open position by the placement of
bsorbable suture material in the interstices of the spring.
hat holds the spring in an open position. The bioabsorb-
ble material dissolves after 1 to 2 months, with slow and
teady shortening of the device as the spring spaces approx-
mate. The effect of the Cardiac Dimensions Carillon device
an be assessed immediately at the time of implant, and even
efore complete release of the device. Thus, if the degree of
eduction in MR is not sufficient, the device can be retrieved
nd the procedure abandoned. However, once the Edwards
onarc device is placed and released, there is no indication
egarding the ultimate efficacy outcome until the spring has
hortened several weeks later. Thus, there is no method to
redict the outcome of MR reduction until after the implant
as been completed and some time has passed. Early
xperience with the Edwards Monarc device has also dem-
nstrated reductions in MR grade 1 or 2 grades in the
ajority of patients. Further study of the Monarc device has
een stopped by the sponsor due to slow enrollment in the
VOLUTION II (Clinical Evaluation of the Edwards
ifesciences Percutaneous Mitral Annuloplasty System for
he Treatment of Mitral Regurgitation) trial.
The Viacor PTMA device has a somewhat different
echanism (10–12). Subclavian puncture is used to deliver
trilumen plastic cannula into the coronary sinus. Stiff
itinol rods are passed through the lumens of the catheter to
pply pressure to the central part of the posterior mitral
eaflet and compress the septolateral dimension, rather than
o encircle and constrict or cinch the mitral annulus. Rods of
arying stiffness may be used. During the implant process, a
equence of rods may be placed through the lumens to
etermine the optimal amount of compression of the
osterior annulus to result in a reduction in MR. Another
ttractive feature of this device is that the subclavian access
ay be re-accessed at a later date to remove rods if there is
ome problem with the device; or if efficacy for reduction of
R is diminished, stiffer rods may be used to replace those
hat were chosen during the initial implant process. The first
everal patients treated with this system have shown con-
inued compression of the mitral orifice for as long as 1 year
fter initial implantation. The company has subsequently
topped further development of the device.
There are several limitations common to all of the
oronary sinus devices. Long-standing prior experience with
oronary sinus pacemaker lead implantation suggested that ahe integrity of the devices would not be a significant
roblem, but all 3 of these devices have experienced metal
atigue, with device fracture in several cases. Apparently, the
echanical stresses of the coronary sinus are greater than
ad been anticipated, and the complex geometric motion
atterns of the coronary sinus create greater torsional forces
n these devices than had been initially modeled using finite
lement analysis. Re-engineering of all 3 of these devices
as led to better outcomes, with improvements in the
requency device fracture. Long-term study will be necessary
o determine whether this remains a persistent late problem.
mportantly, device fracture has not resulted in coronary
inus perforation or other important adverse events. Inter-
stingly, device fracture in patients treated with the carillon
evice has not been associated with loss of efficacy in MR
eduction.
A second important limitation common to this class of
evices is the potential for compression of the circumflex
oronary artery. The coronary sinus crosses over the circum-
ex coronary artery or 1 of its obtuse marginal branches in
etween two-thirds and three-quarters of patients (13–15).
ith the Cardiac Dimensions Carillon device, this com-
ression can be appreciated at the time of implant. The
osition of the implant can be adjusted to diminish com-
ression, or if needed, the device can be removed and the
rocedure abandoned. With the Edwards Monarc device,
he potential for compression cannot be completely assessed
ntil after shortening of the bridge element occurs several
eeks later. Computed tomography scans to evaluate the
elationship of the coronary sinus and the coronary arteries
efore device implantation are therefore particularly impor-
ant with these devices. While the Viacor PTMA device
oes not encircle as much of the circumference of the mitral
nnulus, compression of the circumflex may still occur with
his device as well (16). Thus, evaluation of the coronary
irculation both before the procedure using computed to-
ography scanning and during the implant procedure using
oncurrent coronary arteriography is important as part of
he implant procedure. In early human experience, this
roup of devices was successfully implanted in about two-
hirds of patients. In the remaining one-third, the procedure
as not successful because of either unfavorable coronary
inus geometry, difficult coronary sinus access by the guiding
ystem, or coronary artery compression.
Despite the indirect nature of the coronary sinus ap-
roach and the challenges that have been encountered with
hese devices, the coronary sinus route remains highly
ttractive because of the simplicity of the approach. The
otential for transvenous implantation makes the procedure
ccessible to a large population of patients and a wide range
f physician operators.
irect annuloplasty approaches. Direct implantation of a
evice into the mitral annulus would overcome some of the
imitations of the indirect, coronary sinus approach (17).
irect annuloplasty might more closely mimic surgical
nnuloplasty ring implantation. Reaching the mitral annu-
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Percutaneous Mitral Valve Therapy February 1, 2011:529–37us directly is more challenging than using the coronary
inus approach. A guide catheter must be passed retrograde
ransarterially across the aortic valve and maneuvered into a
osition within the left ventricle under the posterior mitral
eaflet, adjacent to the mitral annulus. Two companies,
itralign and Guided Delivery Systems, have utilized a
irect access approach. Retrograde access to the left ventri-
le and posterior mitral annulus is shared by both of these
evices, but each device is unique.
The Mitralign system (Mitralign, Tewksbury, Massachu-
etts) involves placement of the guide catheter under the
iddle scallop of the posterior mitral leaflet. Radiofre-
uency wires are used to penetrate the mitral annulus and
ain access to the left atrial side of the annulus. Pledgets are
assed over the wires and connected with a drawstring.
lication of the string results in drawing of the pledgets
loser together. The current system employs 2 pairs of
ledgets, and this results in shortening of the mitral circum-
erence by 1 to 3 cm. The system has been employed in
re-clinical and first-in-human experiences. Clinical out-
ome data will require additional experience.
The second direct annuloplasty approach is the Guided
elivery Systems device (Guided Delivery Systems, Santa
lara, California) (Fig. 2). After access to the annulus, a
eries of as many as 12 nitinol anchors are placed in the
itral annulus. These are connected with a tether or cord
hat is tensioned to draw the anchors together. This device
as been implanted surgically, and first-in-human experi-
nce has demonstrated the technical feasibility of percuta-
eous use.
Direct annuloplasty has the advantage of obviating cor-
nary compression. Arterial access as the delivery route adds
ome complexity and morbidity to this procedure in com-
arison with a transvenous coronary sinus approach. The
otential for greater efficacy in reduction of MR through the
irect approach is highly attractive. The direct annuloplasty
echnologies are in early development, and more human
Figure 2 Direct Annuloplasty
The Guided Delivery Systems Accucinch device is delivered through retrograde cat
in the posterior mitral annulus and (right) connected with a “drawstring” to cinchxperience is anticipated. ceaflet Repair
urgical leaflet repair has mainly utilized annuloplasty in
onjunction with the techniques of leaflet resection and
liding annuloplasty. Surgical leaflet approaches are used
or MV prolapse to remove some of the redundant leaflet
issue, and help to restore leaflet coaptation. No percu-
aneous version of leaflet resection is currently available
nd has yet to be developed. A less commonly utilized
urgical leaflet repair approach is the edge-to-edge, or
ouble-orifice repair (18,19). The repair is accomplished
y suturing the free edges of the mitral leaflets together to
orm a double orifice. This surgical procedure was pio-
eered by Alfieri et al. (18) in the early 1990s. In most
ases, annuloplasty is performed in conjunction with
eaflet surgical repair. Isolated use of the edge-to-edge
epair has been controversial, because most surgical
xperience has utilized the combination of annuloplasty
nd the leaflet repair. Follow-up for as long as 12 years in
small group of patients who have undergone isolated
urgical edge-to-edge repair without annuloplasty has
emonstrated durable clinical outcome, and thus proof of
rinciple, with this surgical technique (19). Additional
tudy will be needed to show how well the principle
ranslates into clinical outcome in various populations of
atients.
valve MitraClip. A percutaneous approach has been
eveloped that uses a clip to create the double-orifice repair
20,21). The MitraClip system uses a guide catheter, a clip
elivery catheter, and an implantable clip (Fig. 3). The
uide is placed using transseptal puncture. It is 24-F
roximally and tapers to 22-F at the level of the atrial
eptum, and is delivered over a dilator. A knob on the end
f the guide is used for deflection of the tip. The delivery
atheter passes coaxially through the guide, and has the
itraClip attached to its distal end. This delivery system
ses 2 knobs that control mediolateral and anteroposterior
teering. The MitraClip device is a 4-mm-wide cobalt-
ation of the left ventricle. (Left) Anchors are placed
nular circumference. Figure illustration by Craig Skaggs.heteriz
the anhromium implant with 2 arms. The clip arms are opened
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February 1, 2011:529–37 Percutaneous Mitral Valve Therapynd closed by a knob on the delivery catheter handle. The
lip has a locking mechanism to maintain closure. On the
nner portion of the clip are small barbs or “grippers” to
ecure the leaflets when the clip arms are closed. The clip is
overed with polyester fabric.
Figure 3 The Evalve MitraClip
(A) The Evalve MitraClip. The clip arms are open (left) when the device is passed
barbed piece seen in the upper left panel, parallel to the shaft of the delivery syst
arms (middle). The clip is covered with polyester fabric (right). (B) The steering k
left atrial cavity. At the far left of the picture is the knob that is used to open and
Figure 4 Basic Steps of the Evalve MitraClip Clip Procedure
(Top) The left panel shows the clip being steered through the left atrium toward th
valve (MV) with the clip arms open, before the clip has been pulled back to grasp
(Bottom) In the fluoroscopic figure, the leaflets have been grasped and clipped cloThe procedure is performed with general anesthesia,
sing fluoroscopy and transesophageal echocardiography
uidance (22). Most of the maneuvering of the system is
one using echocardiography (Fig. 4). Transseptal access
s used to place a guide catheter into the left atrium.
the mitral leaflets from the left atrium into the left ventricle. The gripper is the
hen the leaflets are grasped, the gripper helps to fix the leaflets within the clip
re shown on the right-hand side of the device for maneuvering the clip within the
the clip, and the release mechanism.
ter of the mitral orifice. The middle panel illustrates the device across the mitral
tral leaflets. The right panel shows, in the cartoon, the clip has been released.
artially, before full closure and release of the clip.across
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Percutaneous Mitral Valve Therapy February 1, 2011:529–37hrough the guide catheter, the clip delivery system is
aneuvered to center the clip over the mitral orifice. The
lip is partially opened and passed across the leaflets,
hrough the chordae tendineae, and into the left ventri-
le. The open clip is pulled back to grasp the mitral
eaflets. When the leaflets have fallen into the clip arms,
he grippers are lowered, and the clip is closed. A key step
t that point is evaluation of the insertion of leaflet tissue
nto the clip. If the leaflets have been adequately grasped,
determination of the degree of reduction in MR can be
ade. If needed, a second clip can be placed. The clip
ay be opened and closed to grasp the mitral leaflets
everal times. If the leaflet insertion is not adequate, or if
eduction of the MR is insufficient, the clip is opened,
ithdrawn into the left atrium, and repositioned before
rossing the leaflets and attempting another grasp. If after
everal attempts it appears that the degree of MR cannot
e effectively reduced, the clip can be completely re-
oved. Thus, the ability to assess the results of the
rocedure in real time is an important asset of this
herapy.
Patients have been referred for surgical mitral repair after
nsuccessful clip procedures, both with and without a clip in
lace. Successful surgical repair has been accomplished in
his setting (23). The appearance of the leaflets in the
perating room after unsuccessful clip procedures without
lacement of a clip has demonstrated some reddening of the
eaflets, but actual tissue damage or damage to the chordae
as been rare. Successful surgical repair has also been
ccomplished after placement of a clip. In most of these
nstances, MR was either not adequately controlled or it
ecurred after placement of a clip. The clips can be removed
nd surgical repair can be accomplished in the majority of
atients without needing valve replacement. Patients who
ave required valve replacement after failed clip therapy
sually have predictors for replacement such as advanced
ge, annular calcification, or leaflet calcification. Thus, the
otential for utilization of the clip without substantial
enalties regarding future surgical repair is possible.
Patients treated in the Evalve EVEREST (Endovascular
alve Edge-to-Edge Repair Study) have been selected using
he American Heart Association/American College of Car-
iology guideline recommendations for surgical MV repair.
atients with moderate to severe or severe MR (3 to 4),
udged by quantitative assessment of the degree of regurgi-
ation using the American Society for Echocardiography
uantitative scoring system have been included. All of the
chocardiograms have been evaluated in a core laboratory.
se of the American Society for Echocardiography quanti-
ative scoring system is important because, in usual practice,
lthough noninvasive approaches have been widely accepted
o assess severity of MR, there remain significant limita-
ions. There is overlap in measurements for effective regur-
itant orifice area, regurgitant volume, and regurgitant
raction between mild (1) and severe (4) angiographic
R. In practice, patients with qualitative “severe” MR by tchocardiography are frequently found to have no or mild
1)MR on angiography. In the EVEREST andEVEREST II
rials, it was our experience that about one-quarter of
atients referred with a clinical assessment of 3 or 4MR
ad only2MR in the core echocardiography laboratory.
atients were symptomatic, or if asymptomatic, had evi-
ence of LV dysfunction for inclusion for treatment with
he MitraClip. Importantly, patients with severely reduced
V dysfunction with LV ejection fraction of 25% were
xcluded.
On an intent-to-treat basis, 96 (90%) of the 107 EVEREST
rial registry patients achieved a reduction in MR from
ither the clip or subsequent MV surgery after attempted
lip. Of the patients with acute procedure success, 64% were
ischarged with mild MR (1), and 13% hadMR graded as
ild to moderate (1 to 2). Thus, 77% had 2 MR.
bout 40% of patients were treated with 2 clips. The
omposite primary efficacy end point (freedom from MR
2, cardiac surgery for valve dysfunction) and from death
or the per-protocol population at 1 year was 66%, not
ncluding crossover to surgery. Three-year freedom from
eoperation was just under 80%. Results have been similar in
oth degenerative and functional MR.
In-hospital and 30-day complications in the EVEREST
rial registry included major adverse events in 9% of 107
atients. There was no procedural mortality. Bleeding
equiring transfusion was the most common event, compris-
ng almost one-half of the adverse events. There was 1 peri-
rocedural stroke and 1 post-procedure death. One patient
nderwent reoperation for failed surgical MV repair 19 days
fter valve repair after an unsuccessful MitraClip procedure,
nd 1 patient required ventilation for 20 days. No clip
mbolization has occurred at any time point. Partial clip
etachment is the most important mechanical problem with
he procedure. That occurred in 9% of the initial cohort, and
as most often detected at the protocol-mandated 30-day
chocardiography examination. These partial detachments
ere generally not associated with symptoms. Most were
reated with mitral surgery, but more recently in the registry
nd in European experience, an additional clip has been
laced. With better methods for assessment of leaflet
nsertion into the clip at the time of the procedure, the
ncidence of partial clip detachment has declined to 3%.
Careful evaluation of the echocardiographic morphology
f the mitral leaflets is critical for good patient selection
Fig. 5). Patients with either degenerative or functional MR
ave been successfully treated. A coaptation length of at
east 2 mm is needed. Thus, some tissue from both leaflets
hould be in contact, so there is some tissue to grasp with
he clip. With a flail mitral leaflet, a flail gap 10 mm or a
ail width on short-axis estimation 15 mm are also
mportant anatomic features. The MR jet must arise from
he central two-thirds of the line of coaptation as seen on
hort-axis color Doppler examination. It is common for
ost clinical transthoracic echocardiographic examinations
o either omit or have very little short-axis color Doppler
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February 1, 2011:529–37 Percutaneous Mitral Valve Therapynterrogation of the MV. Adequate evaluation for this
herapy requires careful scanning of the mitral funnel in the
hort-axis view to ensure that the jet origin is central, and
deally, relatively discrete. The baseline MV area should be
4 cm2, because placement of the clip significantly dimin-
shes the MV area, and this attention to baseline mitral area
s necessary to avoid the creation of mitral stenosis. Clini-
ally important mitral stenosis has not been created in our
xperience to date because of careful attention to the
aseline MV area during the patient screening and selection
rocess.
A randomized phase II clinical trial comparing the
itraClip with either surgical valve repair or replacement
as been completed. In all, 279 patients have been random-
zed using a 2-to-1 scheme, and 12-month follow-up has
een completed. The results of the trial were presented at
he American College of Cardiology annual scientific ses-
ions in 2010. Safety end points were reached in about 50%
f surgery patients and 15% of MitraClip patients, showing
uperiority of safety for the percutaneous approach by
ntention to treat. A large component of the safety end point
s blood transfusion, which is much more frequent with
Figure 5 Echocardiographic Evaluation of Morphology of Mitral
(Top) A coaptation length of at least 2 mm is needed. Thus, some tissue from bo
(Bottom) With a flail mitral leaflet, a flail gap 10 mm and a flail width on short-a
jet must arise from the central two-thirds of the line of coaptation, as seen on sho
permission, from Feldman et al. (20).alve surgery than with the MitraClip procedure. Patients nho receive transfusions after cardiac surgery have a higher
ortality rate extending beyond 5 years post-operatively
ompared with that of patients who do not receive transfu-
ions, demonstrating the importance of transfusion as a
afety end point (24). The 1-year efficacy end point of the
ombined incidence of death, MV surgery, or reoperation
or MV dysfunction was reached in about three-quarters of
urgery patients and in two-thirds of MitraClip patients,
eeting the noninferiority hypothesis for efficacy. A larger
roportion of surgery patients had 0 to 1MR. Reductions
n LV volumes and dimensions were achieved in both
roups after 1 year, as were improvements in New York
eart Association functional class.
The device has received continuing education approval
nd is undergoing increasingly wide use in Europe. The
xperience in clinical practice has shown several trends.
urrent use in Europe includes a high proportion of
atients at high risk for surgery. A majority of the patients
n the EVEREST registry had degenerative MR, but about
hree-quarters of those being treated in European practice
ave functional MR. The learning curve for new clinical
ites has benefitted from the aggregate experience with this
ets Is Critical for Good Patient Selection
ets should be in contact, so there is some tissue to grasp with the clip.
imation 15 mm are also important anatomic features. The mitral regurgitation
color Doppler examination. Figure illustration by Craig Skaggs. Modified, withLeafl
th leafl
xis est
rt-axisovel procedure. New sites are having high implant success
r
d
r
f
i
o
u
F
T
a
p
M
f
o
e
I
l
o
p
p
p
t
a
f
l
C
t
m
t
r
e
m
f
b
a
o
g
a
L
r
h
d
e
n
d
p
e
a
t
c
r
m
r
s
h
f
R
s
2
t
R
1
1
1
1
1
1
536 Feldman and Cilingiroglu JACC Vol. 57, No. 5, 2011
Percutaneous Mitral Valve Therapy February 1, 2011:529–37ates and good clinical outcomes, with average procedure
evice times (guide catheter insertion to guide catheter
emoval) under 2 h, and for cases with 1 clip implanted,
requently under 1 h. This reflects continued improvements
n procedure technique, and the ability to teach new
perators proper patient selection, the technique, and the
se of intraprocedure echocardiographic guidance.
uture Developments
he best methods for study of these new MV therapeutic
pproaches are difficult to establish. Percutaneous annulo-
lasty approaches have been directed primarily at functional
R. Surgical annuloplasty has been most commonly per-
ormed in conjunction with coronary bypass or other valve
perations. Thus, isolated percutaneous annuloplasty is not
asily compared with surgical annuloplasty. The EVEREST
I trial was unique in being able to compare percutaneous
eaflet therapy directly with surgery. Medical therapy is the
ther possible comparator, especially in high-risk surgery
atients. Measurement of differences in outcome in com-
arisons of medical therapy with devices may be difficult if
atients with 2 MR are studied, whereas patients with 3
o 4 functional MR are less common. In addition to
ssessing decreases in MR grade and LV dimensions,
unctional results such as 6-min walk tests, and quality of
ife measures such as the Short Form-36 and the Kansas
ity Cardiomyopathy questionnaires, are important to de-
ermine the utility of MR therapy devices.
Several novel concepts are in the earliest stages of develop-
ent. Beating-heart transapical chordal replacement is 1 of
hese concepts. Another is catheter-based, percutaneous MV
eplacement. Percutaneous MV replacement is in pre-clinical
valuation. Challenges include the asymmetric shape of the
itral orifice, and finding an adequate anchoring mechanism
or a percutaneous prosthesis. Radiofrequency energy has
een used as an annuloplasty approach to shrink the mitral
nnulus (25).
A fundamental problem with annuloplasty for treatment
f functional MR is that MV dysfunction is caused by LV
eometric distortion and LV chamber dysfunction. While
nnuloplasty treats MR, it has no impact on the underlying
V dysfunction. A novel therapy that effected chamber
emodeling has been developed and tested in a significant
uman experience (26–30). Unfortunately, lack of funding
uring the recent financial crisis led to the demise of this
ffort. The Coapsys system (Myocor, Maple Grove, Min-
esota) used a tether placed through the LV cavity, either
uring beating-heart surgery or through transpericardial
ercutaneous access. The ventricle is compressed between 2
xternal pads placed on the epicardial surface of the anterior
nd posterior walls and connected by the transventricular
ether. This device both remodels the LV chamber and
ompresses the mitral annular septolateral dimension. A
andomized trial comparing Coapsys surgical therapy with
itral annuloplasty for ischemic MR without ventricular
1emodeling has been completed, and demonstrates both
ustained reductions in MR and improved survival (31). It is
oped this technology will come back into development and
urther testing.
eprint requests and correspondence: Dr. Ted Feldman, Evan-
ton Hospital, Cardiology Division, Walgreen Building, 3rd Floor,
650 Ridge Avenue, Evanston, Illinois 60201. E-mail:
feldman@northshore.org.
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